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Abstract 
Assigning the hemocompatibility of small vascular implants is one of the great challenges in biomedical engineering. 
Due to the fact, that there are no widely approved test setups1, we decided to developed a modified CHANDLER-Loop sys-
tem for dynamic in vitro hemocompatibility tests. The setup allows simultaneous testing of about 30 tube rings with an 
inner diameter of 2,4 mm. Cardiovascular implants can be placed into these tube rings. After filling them with anticoagu-
lated blood and closing them to loops, they were placed on a rotating disc. While the loop is rotating, the blood remains 
in the lower part of the loop. The relative movement between the foreign surface and the blood sample induces a blood 
flow without the need of mechanical pumping. A first test series with the new test setup had been conducted to achieve a 
highly hemocompatible tube material. The results were compared to hemocompatibility tests done by LEMM, mentioned 
in the ISO 10993-42,3. We could prove, that Tygon S50HL® and Polyurethane achieve similar hemocompatibility values. 
In addition, we did in vitro tests of bare metal stents. We recorded a difference in the index of thrombocytes of about 
17 % between the loops with three stents and the control. During further experiments the difference decreases to 8 %, 
which might be due to adhesion processes. The ability to measure these processes demonstrates the high sensitivity and 
very low background activation of the test setup. This can be assured by the recorded index of hemolysis, which had 
been less than 0,8 % in all our experiments.  
By developing and improving our modified CHANDLER-Loop system, we were able to establish a dynamic in vitro test 
setup for the hemocompatibility testing of small vascular implants. Because of its extremely low background activation 
and a high variability, the system serves as a benchmark for upcoming test setups.   
 
1 Introduction 
Approximately 4 million stents are implanted annually 
worldwide4. The resultant foreign surface contact leads to 
an activation of the human coagulation system, which is 
normally inhibited by the application of anticoagulants. 
Due to these interactions between implants and human 
blood flow, materials used for the fabrication of cardiovas-
cular devices must be highly hemocompatible. According 
to the ISO 10993-4 dynamic in vitro test setups are suitable 
screening methods to assign the hemocompatibility of 
small vascular implants3. A great challenge in the devel-
opment of such test setups lies in the ratio between the 
small test material surfaces and the surfaces of components 
used for the blood handling. A background activation 
caused by these components may overlay the implant sig-
nal, so that a measurable implant effect is reduced5. In ad-
dition, there are no widely approved test setups or an 
agreed list of hemocompatible materials1. Moreover the 
reproducibility of dynamic hemocompatibility tests is 
made difficult due to missing information about test pa-
rameters and conditions6.  
Because of its low background activation, which is real-
ized by inducing a blood flow without the need of a me-
chanical pump system, the CHANDLER-Loop is a widely 
used setup for hemocompatibility testing of small vascular 
implants7. For this reason we decided to develop a modi-
fied CHANDLER-Loop, which should be used as a bench-
mark system for more complex in vitro setups. 
1.1 In vitro hemocompatibility testing 
The blood contact to a foreign surface is followed by a rap-
id plasma protein adsorption, which leads to the activation 
of the coagulation system. In addition, the surface contact 
or mechanical forces can cause a damage of the red blood 
cell membrane, which results in hemolysis. As previously 
mentioned, these surface interactions occur at the implant 
materials as well as at the blood handling components. Be-
cause of this, the blood damage, which is induced by the 
test setup, should be very low and well defined. 
In 1958 CHANDLER developed a test system for analyzing 
the coagulation system. Native whole blood was filled into 
tubes, which were closed to loops. While rotating on a disc 
which is held in a 23° angle, the blood remains in the low-
er part of the loop, which results in a relative movement 
between tube surface and blood. By measuring the time 
until the tube was clotted through a thrombus, CHANDLER 
was able to analyze the functionality of the coagulation 
system. 
1.2 Modified CHANDLER-Loop 
The developed tube ring holder can be connected to a 
common roller pump (BVP Standard, ISMATEC), which 
facilitates an accurate adjustment of the rotation speed and 
a hemocompatibility testing in almost every laboratory. 
The whole setup is placed in a chamber, which is regulated 
at 37 °C.  
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A disc with a diameter of 220 mm is mounted on mandrel, 
which is part of the constructed connection plate between 
test setup and roller pump. 
 
  
Figure 1 Adjustable tube ring holder, shown for the mini-
mum diameter (left) and the maximum diameter (right). 
 
The developed mechanism allows a variable radial move-
ment of stainless steel pins with a length of 150 mm. This 
realizes a simultaneous rotation of up to 30 specimen with 
a various loop diameter between 110 – 220 mm, which ap-
proves a comparison between different materials or in case 
of implant testing, the reference to a control. Moreover, by 
removing loops from the test setup, it is possible to analyze 
blood samples at different points of the testing time. 
2 Materials and Methods 
Regarding the direct blood contact of the tube rings used 
as blood handling system, we had to investigate a highly 
hemocompatible tube material to minimize the background 
activation, which otherwise may overlay our implant sig-
nal. Our first experiment was designed in reference to a 
hemocompatibility test series, which was conducted by 
LEMM2,8. While LEMM performed his tests with tubes made 
of Polyethylene, Polyurethane, Silicone, Polyvinylchloride 
(plasticized / unplasticized) and Polypropylene, we chose 
tubes the following materials: 
 
• Silicone (SIK 8363, RAUMEDIC)  
• Polyvinylchloride (PVC Guttasyn TOL) 
• Tygon B44-EU® noDOP  
• Tygon S50HL® medical tubing (both SAINT-
GOBAIN - PERFORMANCE PLASTICS) 
 
LEMMS setup was quite similar to a CHANDLER-Loop sys-
tem and by taking the same surface/volume ratio (25 1/cm) 
and flow velocity (18,8 cm/s), we were able to facilitate a 
good comparability. While choosing the same inner diame-
ter of 4 mm we had to reduce the blood volume to 3 ml 
and the tube length to 61 cm. 
A second test series with bare metal stents was performed 
to prove the sensitivity of our new dynamic test setup, by 
showing that the blood damage, induced by the blood han-
dling components, still allows a measureable implant sig-
nal. The stents were placed in tubes of Polyurethane (El-
lastollan®, BASF) with an inner diameter of 2,4 mm and a 
length of 68 cm. We prepared three different loop types, 
one without any stent, serving as control for the back-
ground activation, loops containing one stent (l = 19 mm) 
and loops with three stents (2 x l = 18 mm and 1 x l = 
19 mm). After every experiment the loops were washed 
with Triton X 100 (CARL ROTH GMBH & CO. KG) to allow 
further test runs. 
Tubes were filled with 3 ml (ø = 4 mm) or 1,5 ml 
(ø = 2,4 mm) anticoagulated porcine blood (heparin, 
5 IU/ml blood) and closed to a loop by using 2 – 4 cm long 
tubes, whose inner diameter were of the same dimension 
as the outer diameter of the tested tubes. After the com-
pleted test duration, blood was taken out of the tubes and 
the parameters hematocrit, hemolysis and thrombocyte 
count were determined. 60 µl of whole blood was filled 
into small capillaries (BRAND GMBH & CO. KG) and after 
a following centrifugation step (11.000 g, 4 min) the hema-
tocrit could be noted. These values were related to the zero 
value, which allows a compensation of physiological var-
iations in the blood samples and improves the comparabil-
ity between different test days. Referring to the 
ISO 10993-4 hemolysis is a standard parameter that should 
be determined while testing the hemocompatibility of bio-
materials3. The index of hemolysis is defined by the fol-
lowing formula9: 
 
 
 
 
 
• IH = index of hemolysis [%] 
• HCT = Hematocrit [-] 
• PHb = Plasma hemoglobin [g/dl] 
• THb = Total hemoglobin [g/dl] 
 
The total hemoglobin represents the amount of hemoglobin 
in the whole blood, while the plasma hemoglobin describes 
the free hemoglobin in the blood plasma. An increasing 
value of plasma hemoglobin indicates a damage of the red 
blood cell membrane, which causes a release of hemoglo-
bin.  Both parameters were measured with a Photometer by 
using a test solution (Hemoglobin FS, DIASYS). To assign 
the activation of the coagulation system we did a thrombo-
cyte count of every blood sample. Therefore 20 µl of 
whole blood were mixed with a dyeing solution (TVT-
Thrombozyten-Einzeltest, KABE) and after a short incuba-
tion of about 3 min the mixture was injected into a glass 
chamber (Neubauerkammer, PAUL MARIENFELD GMBH & 
CO. KG), which was used for the cell counting. The count-
ed cell numbers were related to the zero value by using the 
following index: 
 
 
 
 
• TI = Index of thrombocytes [%] 
• TCX = Thrombocyte count at point x [1/µl] 
• TC0 = Zero value [1/µl] 
 
A decrease in the index might be caused by an adhesion of 
cells to the foreign surface or cell aggregation. 
TI [%]= TCXTCo
•100%
IH [%]=
1− HCT100
"
#
$
%
&
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3 Results 
The values of the hematocrit showed neither an increase 
nor a decrease for all tested materials or implants. Fur-
thermore, the index of hemolysis had always been less 
than 0,8 %, from which reason the results were not pre-
sented in detail. 
 
Figure 2: Index of thrombocytes, shown for all tested ma-
terials. Samples were taken at 1, 2, 3 and 4 hours (n = 3). 
 
We could observe the greatest decrease of thrombocytes 
within the first hour of our experiment. The best result was 
recorded with a 20 % lowering for Tygon S50HL®. After 
four hours of testing, Tygon S50HL® showed the lowest 
loss of thrombocytes, while SIK 8363 induced the greatest 
decrease. The results of the two other materials looked 
similar. 
Figure 3 represents the results of the bare metal stent tests 
with increasing number of test days. We compared the 
values of the control (no Stent) and the loops with three 
stents, because their differences were more pronounced. 
Within the first hour the loss of thrombocytes is about 
20 % for the control. Furthermore the loops with three 
stents are showing a decrease of another 17 % compared to 
control. The difference is reduced with the increasing 
number of test days. 
 
Figure 3: Index of thrombocytes, shown for the loops with 
three stents and the control. Samples were taken after one 
hour of dynamic testing (n = 5).  
4 Discussion 
Regarding constant values of the hematocrit measurement 
and the very low index of hemolysis, we could prove that 
our system induces an extremely low background activa-
tion. In comparison to the hemocompatibility tests per-
formed by LEMM, we achieved similar results for SIK 
8363, which was marked with a decrease of thrombocytes 
of about 50 % after one hour. The smallest loss of throm-
bocytes could be observed for Tygon S50HL®, whose he-
mocompatibility, compared to the results from LEMM, is 
almost equal hemocompatibility to Polyurethane. Regard-
ing the great decrease in thrombocytes during the first 
hour, followed by smaller steps of decrease over the time, 
we could prove the statement of BLACKSHEAR & BLACK-
SHEAR whereas the materials surface has the largest influ-
ence on the blood damage during the first test hour10. 
Considering the results of the bare metal stent testing, we 
recorded meaningful differences between control and 
loops with three stents. This measurable effect, induced 
from small cardiovascular implants, demonstrates the high 
sensitivity of the in vitro test setup, which was already 
mentioned by CHRISTENSEN ET. AL, who stated that the 
CHANDLER-Loop is effective test model for assigning he-
mocompatibility of stents or vascular grafts11. 
Due to further development of our modified CHANDLER-
Loop, we could establish a benchmark system for dynamic  
for hemocompatibility testing at the Institute for Multi-
phase Processes. Because of the very low background acti-
vation combined with its variable specimen holder, the 
modified CHANDLER-Loop is an ideal test setup for dy-
namic hemocompatibility testing of small vascular im-
plants. 
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